Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787369 · ClinicalTrials.gov registry record · Phase 1
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
A Phase 1 study of Recurrent Chronic Lymphoid Leukemia, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02787369 is a Phase 1 study of Recurrent Chronic Lymphoid Leukemia that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02787369, a Phase 1 study of Recurrent Chronic Lymphoid Leukemia, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Conditions Studied
Interventions
- DRUG Ibrutinib
- DRUG Idelalisib
- DRUG ACY-1215
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-05 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02787369
The ClinicalTrials.gov registry entry for NCT02787369 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Chronic Lymphoid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Ibrutinib is the first listed.
NCT02787369 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02787369 about?
NCT02787369 is a clinical study titled "ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL". This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
What is the current status of trial NCT02787369?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-05. Estimated completion is 2027-04.
What conditions does trial NCT02787369 study?
This clinical trial studies the following conditions: Recurrent Chronic Lymphoid Leukemia.
What interventions are being tested in trial NCT02787369?
The interventions under investigation include: Ibrutinib (DRUG), Idelalisib (DRUG), ACY-1215 (DRUG).
Who is sponsoring clinical trial NCT02787369?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02787369 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.